Bruker's Adjusted Margin Jumps To 16.3% As A $174.5 Million Goodwill Charge Drives A Loss
Revenue rose 1.6% to $874.0 million, and the company held its 2026 adjusted earnings forecast of $2.10 to $2.15 per share.
Bruker, which makes scientific instruments for research labs, drug developers and hospitals, lifted its third-quarter adjusted operating margin to 16.3%, up from 12.3% a year earlier, while sales grew just 1.6%. A non-cash goodwill impairment of $174.5 million pushed it to a loss on a standard-accounting basis, the company said Wednesday in an 8-K.
Cost cuts lift adjusted profit
Adjusted earnings per share rose 24.4% to $0.56 from $0.45. Adjusted operating income was $142.6 million, against $105.9 million a year earlier.
On a standard-accounting basis, Bruker lost $0.81 per share, compared with a loss of $0.41 a year earlier. The operating loss was $91.0 million, against $51.8 million in the prior-year quarter.
CEO Frank H. Laukien credited the margin gain to "our focus on cost discipline and execution." Selling and administrative expenses fell to $226.5 million from $242.5 million, and research spending to $92.0 million from $98.3 million.
Thin growth, with a bright spot in energy
Revenue of $874.0 million compared with $860.5 million a year earlier, and organic growth, which strips out acquisitions and currency, was 0.7%. Acquisitions added 1.7%, and currency subtracted 0.8%.
The larger instruments business, Bruker Scientific Instruments, brought in $793.9 million, up 0.8%, with organic revenue down 0.4%. The Bruker Energy & Supercon Technologies unit rose 11.2% to $82.1 million.
Laukien said the instruments unit's book-to-bill ratio, orders relative to sales, topped one for a fifth straight quarter. He also said demand was strengthening in most end markets, including US academia this quarter.
Cash flow turns positive; forecast held
Free cash flow was $96.7 million, against negative $54.1 million a year earlier. Cash on hand fell to $119.7 million at September 30 from $298.8 million at the end of 2025.
Bruker reconfirmed 2026 adjusted EPS of $2.10 to $2.15, versus $1.83 last year. It now expects revenue of $3.52 billion to $3.56 billion, with currency neutral to revenue rather than the 0.5% boost it had earlier projected. Organic growth is guided to 1% to 2%.
For 2027, Laukien said he expects faster revenue growth, further margin expansion and double-digit EPS growth. Management discusses the results on a call at 8:30 a.m. Eastern on Wednesday.
For the first nine months, Bruker's adjusted operating margin was 13.6%, up from 11.4%, while revenue fell 0.3% organically.
Sources
- 8-K Filing — BRUKER CORP (BRKR) — SEC EDGAR
- Exhibit brkr-ex99_1.htm — BRUKER CORP 8-K exhibit — SEC EDGAR